Y14_RBM8 Inhibitors

Y14_RBM8 inhibitors, as referenced in this context, primarily target RNA splicing and RNA-related processes within the cell. Compounds like Spliceostatin A, Pladienolide B, and Meayamycin exhibit direct interactions with the splicing factor SF3b, a critical component of the spliceosome. These interactions can disrupt spliceosome function, indirectly influencing the activity of Y14_RBM8 or RBM8A, which plays a role in post-transcriptional events. Etoposide, a topoisomerase II inhibitor, can impact RNA splicing indirectly, given the enzyme's significance in DNA replication and transcription. Similarly, 17-AAG, an Hsp90 inhibitor, affects multiple cellular processes, including RNA splicing.

Chemicals such as Isoginkgetin and Silvestrol take a slightly different route. Isoginkgetin inhibits spliceosome assembly, while Silvestrol targets the RNA helicase eIF4A, leading to changes in RNA metabolism. Collectively, these compounds, although not direct inhibitors of Y14_RBM8, play pivotal roles in modulating RNA-related pathways and processes in which RBM8A is a crucial component.